Abstract 170P
Background
Treatment landscape in metastatic lung cancer is quickly evolving and is associated with improved survival but also increased costs. However, epidemiological data on the survival and costs of patients at metastatic stage are limited. This study aimed to describe change in epidemiological data and costs of these patients between 2013 and 2021.
Methods
From the French national claims database (SNDS), a dynamic cohort of patients identified between 2013 and 2021 with metastatic lung cancer and a marker for the presence of metastases (ICD-10 code or at least one reimbursement for Bevacizumab or Pemetrexed) was constituted. A patient was considered as newly diagnosed if no other marker of the presence of metastases were identified in the 7 years prior to inclusion in the cohort. A trend analysis of the rate of newly diagnosed metastatic patients, the proportion of deaths and the mean monthly cost per patient over the period 2013-2021 was performed using Joinpoint software.
Results
147,760 metastatic lung cancer patients were identified between 2013 and 2021: 66.5% of men, with a median age of 66 years. Between 2013 and 2021, a statistically significant decrease in the crude rate of newly diagnosed metastatic patients was highlighted in men (-1.18% per year in average), whereas a statistically significant increase was described in women (+2.36% per year in average). A statistically significant decrease in the proportion of deaths was described for both men and women (-4.37% and -5.07% per year on average, respectively). The mean monthly cost per patient decreased from 2013 to 2015 (from 5,685€ to 4,790€), by 8.90% per year (95%CI: -15.67 to -1.59), then stabilized (1.35%; 95%CI: -0.12 to 2.84).
Conclusions
This study provides unpublished epidemiological data on metastatic lung cancer in France and confirms differentiated trends in the number of newly diagnosed metastatic patients in men and women, already observed for all stages combined. A statistically significant decrease in the proportion of deaths among metastatic lung cancer patients is observed in both gender over the study period. The mean monthly cost per patient initially decreased, then stabilized between 2015 and 2021.
Legal entity responsible for the study
MSD France.
Funding
MSD France.
Disclosure
G. de Pouvourville: Financial Interests, Personal, Advisory Board: MSD France, GSK, Abbott, Takeda-Shire, AstraZeneca, BMS, Edwards Life Sciences, Roche, Alexion, Janssen, Bayer, Biogen, Coloplast, Immedica, Moderna; Financial Interests, Personal, Advisory Role, Expert member of EURECCA a global initiative to improve market access: Novartis; Financial Interests, Personal, Advisory Role, Expert Panel on vaccination: EFPIA; Financial Interests, Personal, Advisory Role: Boehringer Ingelheim, Lundbeck. C. Chouaid: Financial Interests, Personal, Advisory Board: AZ, BI, GSK, Roche, Sanofi Aventis, BMS , MSD, Lilly, Novartis, Pfizer, Takeda, Bayer, Janssen and Amgen; Financial Interests, Institutional, Funding: AZ, BI, GSK, Roche, Sanofi Aventis, BMS, MSD, Lilly, Novartis, Pfizer, Takeda, Bayer, Janssen and Amgen. C. Marchal: Financial Interests, Personal, Full or part-time Employment: PELyon; Financial Interests, Institutional, Funding: MSD France. L. Bensimon, M. Apert, V. Guimard: Financial Interests, Personal, Stocks/Shares: MSD France. M. Née, M. Belhassen: Financial Interests, Personal, Full or part-time Employment: PELyon; Financial Interests, Institutional, Funding: MSD France. J. Blay: Financial Interests, Institutional, Invited Speaker: MSD , MSD, PharmaMar; Financial Interests, Institutional, Advisory Board: Bayer, GSK, Roche; Financial Interests, Personal, Advisory Board: Deciphera; Financial Interests, Personal, Other, member of the supervisory board. No remunerations in 2021 and 2022: Innate pharma; Financial Interests, Personal, Member of Board of Directors: Transgene; Financial Interests, Institutional, Funding: MSD, BMS, Deciphera; Financial Interests, Institutional, Research Grant: AstraZeneca, Roche, Bayer, GSK, Novartis, OSE pharma.